Literature DB >> 9672626

Characterization of T cell responses to herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) using a TNF-beta ELISpot cytokine assay.

D S Schmid1, M L Thieme, H E Gary, W C Reeves.   

Abstract

We examined the suitability of a TNF-beta cytokine ELISpot assay for assessing various aspects of the T cell response to herpes simplex viruses. The number of T cells responding to HSV-1 or HSV-2 was measured by TNF-beta ELISpot assay. The number of T cells producing TNF-beta in response to HSV-1 was high, ranging from 76 to 222 per 10(5). HSV-1-specific TNF-beta-secreting responder cell frequencies fluctuated over time in individual donors. Comparable fluctuations were not observed in the T cell frequencies to phytohemaglutinin (PHA). Responder cell frequencies to glycoproteins gB and gD of HSV-2 accounted for a large number of the HSV-2-specific T cells as measured using the TNF-beta ELISpot assay. Type-specific and type-common components of the T cell response to HSV-1 and HSV-2 could be estimated with this assay. Type-common responder cells typically accounted for 25-30%. Finally, CD4+ and CD8+ TNF-beta-producing T cells were stimulated by HSV-1 at a CD4:CD8 ratio of 2:1, indicating that both major subsets of T lymphocytes are activated by HSV.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9672626     DOI: 10.1007/s007050050187

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  4 in total

1.  Tegument-specific, virus-reactive CD4 T cells localize to the cornea in herpes simplex virus interstitial keratitis in humans.

Authors:  D M Koelle; S N Reymond; H Chen; W W Kwok; C McClurkan; T Gyaltsong; E W Petersdorf; W Rotkis; A R Talley; D A Harrison
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Peripheral blood CD4 T-cell and plasmacytoid dendritic cell (pDC) reactivity to herpes simplex virus 2 and pDC number do not correlate with the clinical or virologic severity of recurrent genital herpes.

Authors:  Nicholas J Moss; Amalia Magaret; Kerry J Laing; Angela Shaulov Kask; Minna Wang; Karen E Mark; Joshua T Schiffer; Anna Wald; David M Koelle
Journal:  J Virol       Date:  2012-07-03       Impact factor: 5.103

Review 3.  Recent progress in herpes simplex virus immunobiology and vaccine research.

Authors:  David M Koelle; Lawrence Corey
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

4.  Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: a double-blind randomized trial.

Authors:  Geert Leroux-Roels; Frédéric Clément; Pierre Vandepapelière; Marc Fourneau; Thomas C Heineman; Gary Dubin
Journal:  Hum Vaccin Immunother       Date:  2013-02-22       Impact factor: 3.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.